Title : Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors.

Pub. Date : 2020 Dec

PMID : 32377978






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 DFP-11207 is a novel oral cytotoxic agent that combines a 5-FU pro-drug with a reversible DPD inhibitor and a potent inhibitor of OPRT, resulting in enhanced pharmacological activity of 5-FU with decreased gastrointestinal and myelosuppressive toxicities. Fluorouracil dihydropyrimidine dehydrogenase Homo sapiens